Podium to Practice: EHA 2026 – Lymphoma: Real-World Bispecifics in LBCL
OR
Studies / Trials Discussed
S240 – REAL WORLD EXPERIENCE OF GLOFITAMAB AND EPCORITAMAB FOR LARGE B CELL LYMPHOMA IN THE UK: EXTENDED ANALYSIS OF DURATION OF REMISSION AND FACTORS AFFECTING RESPONSE IN A COHORT OF 324 PATIENTS
Co-Chairs
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
This program has been made possible through unrestricted support from Merck.
Studies/trials discussed:
S240 – REAL WORLD EXPERIENCE OF GLOFITAMAB AND EPCORITAMAB FOR LARGE B CELL LYMPHOMA IN THE UK: EXTENDED ANALYSIS OF DURATION OF REMISSION AND FACTORS AFFECTING RESPONSE IN A COHORT OF 324 PATIENTS
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.